UPDATE 2-BioCryst delays influenza drug study, seeks more funds

Thu Jan 13, 2011 10:36am EST

* Requests change in efficacy analysis

* Says study may not reach enrollment goals before yr end

* Another study shows drug reduces viral concentration

* Shares down 9 pct (Recasts, updates share movement)

Jan 13 (Reuters) - BioCryst Pharmaceuticals Inc (BCRX.O) delayed enrollment in a late-stage study of its key experimental influenza drug and sought more funds from the U.S. health department, sending its shares down 7 percent.

BioCryst also requested a change in the way it analyzes the drug's efficacy and said it was unlikely the study will reach its enrollment goal before 2011 end.

The drug, peramivir, is being developed under a $180 million contract from the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services.

The study aims to evaluate the efficacy of peramivir when administered intravenously once daily along with the standard of care, versus the standard of care alone.

The company also said another late-stage study showed that peramivir reduced virus concentration. Preliminary data from the study also showed the drug was safe and well-tolerated.

U.S. health regulators have already authorized peramivir for emergency use in the treatment of H1N1 infection.

BioCryst shares were down 9 percent at $4.71 in morning trade on Thursday on Nasdaq. (Reporting by Shravya Jain in Bangalore; Editing by Vinu Pilakkott)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
kiwiarse wrote:
“U.S. health regulators have already authorized peramivir for emergency use in the treatment of H1N1 infection.”

Hey Reuters Guy – The EUA that was issued for “P” during the swine flu pandemic has long ago expired. Peramivir is currently NOT authorized for emergency use in the treatment of H1N1.

Jan 13, 2011 11:22am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.